title: Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions.
abstract: Hypersensitivity reactions to systemically administered drugs cannot be predicted using available preclinical models. This research is a collaborative project to evaluate the ability of the Lymph Node Proliferation Assay (LNPA) to predict systemic hypersensitivity caused by pharmaceuticals. The assay design is a modification of the Local Lymph Node Assay with the major modification being injection of the test substance subcutaneously to achieve a known systemic exposure to the drug. Fourteen compounds were evaluated in the LNPA. These were two clinically negative drugs (Metformin, phenobarbital), an assay positive control (streptozotocin), eight human hypersensitivity positive drugs (sulfamethoxazole, procainamide, clonidine, ofloxacin, nevirapine, abacavir, lamotrigine, zomepirac), and 3 investigational drugs (CM40874, CM40954 and CM40420), one of which caused hypersensitivity in primates. Hypersensitivity-positive drugs were classified as such based on at least two of three independent data sources: U.S. FDA postmarketing database, drug labeling information, and clinical trial data. All drugs were tested in multiple laboratories for a total of 2-12 evaluations per compound. The pure drug substance was used for testing if it could be obtained commercially, otherwise the marketed drug formulation was used. Neither of the negative control drugs showed a positive reaction in the test system. Four of the eight hypersensitivity positive drugs showed a mixed or positive reaction. Two of the three investigational compounds gave a positive response. A smaller number of LNPAs were run concurrently using footpad injection and evaluation of the popliteal lymph node and gave generally comparable results. Additional development may increase the reproducibility of the assay and facilitate detection of drugs that require metabolic activation to become allergenic, or drugs for which there is dose-limiting toxicity. The data suggest that this method might be useful as a first-line screen to identify candidate drugs that are more likely to cause a high prevalence of human drug hypersensitivity.
authors.affiliation: Division of Applied Pharmacology Research, CDER, U.S. FDA, Silver Spring, Maryland, USA.
authors.forename: James L
authors.initials: JL
authors.lastname: Weaver
authors.forename: Joan M
authors.initials: JM
authors.lastname: Chapdelaine
authors.forename: Jacques
authors.initials: J
authors.lastname: Descotes
authors.forename: Dori
authors.initials: D
authors.lastname: Germolec
authors.forename: Mike
authors.initials: M
authors.lastname: Holsapple
authors.forename: Robert
authors.initials: R
authors.lastname: House
authors.forename: Herve
authors.initials: H
authors.lastname: Lebrec
authors.forename: Jean
authors.initials: J
authors.lastname: Meade
authors.forename: Raymond
authors.initials: R
authors.lastname: Pieters
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Hastings
authors.forename: Jack H
authors.initials: JH
authors.lastname: Dean